GLP-1 Cost by State: Medicaid Coverage Map (2026)

How Medicaid GLP-1 Coverage Works

Medicaid is a joint federal-state program, and each state has significant discretion over which medications it covers. The federal Medicaid Drug Rebate Program requires states to cover most FDA-approved drugs from participating manufacturers, but there is a critical exception: states are not required to cover medications used for weight loss.

This exemption has historically meant that anti-obesity medications (AOMs) like Wegovy and Zepbound are excluded from most state Medicaid formularies. However, the landscape is shifting rapidly:

• The Treat and Reduce Obesity Act and similar federal efforts are pushing states toward coverage
• Growing clinical evidence supporting GLP-1 medications for cardiovascular risk reduction has led some states to cover them under cardiometabolic indications
• CMS guidance issued in late 2025 encouraged (but did not require) states to add GLP-1 coverage
• Several states have added or expanded coverage in 2025–2026

Coverage can mean different things in different states. Some cover GLP-1 medications only for diabetes. Others cover them for obesity but with strict prior authorization requirements (BMI 40+, or BMI 35+ with comorbidities). A few states cover them broadly with standard obesity criteria (BMI 30+).

States with Best Coverage

The following states have the most comprehensive Medicaid coverage for GLP-1 weight loss medications as of March 2026:

States with No Medicaid GLP-1 Obesity Coverage

As of March 2026, 14 states do not cover any GLP-1 medication for obesity through their Medicaid programs. These states may still cover Ozempic or Mounjaro for type 2 diabetes, but not for weight loss:

If you live in one of these states, your options for affordable GLP-1 access include:

• Patient assistance programs: NovoCare (Wegovy) and Lilly Cares (Zepbound) provide free medication for income-qualified patients regardless of state
• LillyDirect: Zepbound at $349/month, available nationwide
• Oral Wegovy: $149/month at lowest dose, available at retail pharmacies
• Appeal: If you have a weight-related condition (cardiovascular disease, sleep apnea, type 2 diabetes), your doctor may be able to obtain coverage under a medical necessity exception

How to Check Your State's Coverage

Medicaid formularies change frequently, and the information above reflects our most recent research as of March 2026. To verify current coverage in your state:

1. Contact your Medicaid managed care plan directly. Most states contract with multiple managed care organizations (MCOs), and each may have different formulary rules. Call the number on the back of your Medicaid card.
2. Search your state's preferred drug list (PDL).Most states publish their Medicaid formulary online. Search for "[your state] Medicaid preferred drug list" and look for semaglutide, tirzepatide, Wegovy, or Zepbound.
3. Ask your prescriber to submit a prior authorization. Even in states without formulary coverage, some patients obtain approval through medical necessity exceptions, especially if they have cardiovascular disease, type 2 diabetes, or sleep apnea.
4. Contact a patient advocacy organization. The Obesity Action Coalition (OAC) maintains resources for navigating insurance coverage for weight management medications.

Medicare Coverage for 65+

If you are 65 or older, Medicaid coverage may be less relevant — Medicare is your primary insurance. Starting July 2026, Medicare Part D will cover Wegovy and Zepbound for obesity through a Bridge program:

• Estimated copay: $50/month
• Eligibility: BMI 30+ or BMI 27+ with weight-related condition
• Covered medications: Wegovy (injectable and oral), Zepbound
• Prior authorization: Required

For dual-eligible patients (those on both Medicare and Medicaid), Medicare Part D will be the primary payer for GLP-1 medications starting July 2026. This is a significant improvement for low-income seniors who currently have no coverage path.

Read our complete Medicare GLP-1 Coverage Guide for details on enrollment, eligibility, and how to prepare.